Mulligan LM: RET revisited: expanding the oncogenic portfolio. Nat Rev. 2014, 14 (3): 173-186. 10.1038/nrc3680.
Article
CAS
Google Scholar
Plaza-Menacho I, Burzynski GM, de Groot JW, Eggen BJ, Hofstra RM: Current concepts in RET-related genetics, signaling and therapeutics. Trends Genet. 2006, 22 (11): 627-636. 10.1016/j.tig.2006.09.005.
Article
CAS
PubMed
Google Scholar
Cassinelli G, Favini E, Degl’Innocenti D, Salvi A, De Petro G, Pierotti MA, Zunino F, Borrello MG, Lanzi C: RET/PTC1-driven neoplastic transformation and proinvasive phenotype of human thyrocytes involve Met induction and beta-catenin nuclear translocation. Neoplasia. 2009, 11 (1): 10-21.
Article
CAS
PubMed
PubMed Central
Google Scholar
Croyle M, Akeno N, Knauf JA, Fabbro D, Chen X, Baumgartner JE, Lane HA, Fagin JA: RET/PTC-induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR. Cancer Res. 2008, 68 (11): 4183-4191. 10.1158/0008-5472.CAN-08-0413.
Article
CAS
PubMed
PubMed Central
Google Scholar
Plaza-Menacho I, Morandi A, Robertson D, Pancholi S, Drury S, Dowsett M, Martin LA, Isacke CM: Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance. Oncogene. 2010, 29 (33): 4648-4657. 10.1038/onc.2010.209.
Article
CAS
PubMed
Google Scholar
Wang C, Mayer JA, Mazumdar A, Brown PH: The rearranged during transfection/papillary thyroid carcinoma tyrosine kinase is an estrogen-dependent gene required for the growth of estrogen receptor positive breast cancer cells. Breast Cancer Res Treat. 2011, 133 (2): 487-500.
Article
PubMed
PubMed Central
Google Scholar
Kohno T, Ichikawa H, Totoki Y, Yasuda K, Hiramoto M, Nammo T, Sakamoto H, Tsuta K, Furuta K, Shimada Y, Iwakawa R, Ogiwara H, Oike T, Enari M, Schetter AJ, Okayama H, Haugen A, Skaug V, Chiku S, Yamanaka I, Arai Y, Watanabe S, Sekine I, Ogawa S, Harris CC, Tsuda H, Yoshida T, Yokota J, Shibata T: KIF5B-RET fusions in lung adenocarcinoma. Nat Med. 2012, 18 (3): 375-377. 10.1038/nm.2644.
Article
CAS
PubMed
Google Scholar
Lipson D, Capelletti M, Yelensky R, Otto G, Parker A, Jarosz M, Curran JA, Balasubramanian S, Bloom T, Brennan KW, Donahue A, Downing SR, Frampton GM, Garcia L, Juhn F, Mitchell KC, White E, White J, Zwirko Z, Peretz T, Nechushtan H, Soussan-Gutman L, Kim J, Sasaki H, Kim HR, Park SI, Ercan D, Sheehan CE, Ross JS, Cronin MT, et al: Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med. 2012, 18 (3): 382-384. 10.1038/nm.2673.
Article
CAS
PubMed
PubMed Central
Google Scholar
Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S, Asaka R, Hamanaka W, Ninomiya H, Uehara H, Lim Choi Y, Satoh Y, Okumura S, Nakagawa K, Mano H, Ishikawa Y: RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012, 18 (3): 378-381. 10.1038/nm.2658.
Article
CAS
PubMed
Google Scholar
Moelling K, Schad K, Bosse M, Zimmermann S, Schweneker M: Regulation of Raf-Akt Cross-talk. J Biol Chem. 2002, 277 (34): 31099-31106. 10.1074/jbc.M111974200.
Article
CAS
PubMed
Google Scholar
Wimmer R, Baccarini M: Partner exchange: protein-protein interactions in the Raf pathway. Trends Biochem Sci. 2010, 35 (12): 660-668. 10.1016/j.tibs.2010.06.001.
Article
CAS
PubMed
Google Scholar
Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N: RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature. 2010, 464 (7287): 427-430. 10.1038/nature08902.
Article
CAS
PubMed
PubMed Central
Google Scholar
Cohen P: Guidelines for the effective use of chemical inhibitors of protein function to understand their roles in cell regulation. Biochem J. 2010, 425 (1): 53-54. 10.1042/BJ20091428.
Article
CAS
Google Scholar
Putyrski M, Schultz C: Protein translocation as a tool: The current rapamycin story. FEBS Lett. 2012, 586 (15): 2097-2105. 10.1016/j.febslet.2012.04.061.
Article
CAS
PubMed
Google Scholar
Chappell WH, Steelman LS, Long JM, Kempf RC, Abrams SL, Franklin RA, Bäsecke J, Stivala F, Donia M, Fagone P, Malaponte G, Mazzarino MC, Nicoletti F, Libra M, Maksimovic-Ivanic D, Mijatovic S, Montalto G, Cervello M, Laidler P, Milella M, Tafuri A, Bonati A, Evangelisti C, Cocco L, Martelli AM, McCubrey JA: Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget. 2011, 2 (3): 135-164.
Article
PubMed
PubMed Central
Google Scholar
McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Franklin RA, Montalto G, Cervello M, Libra M, Candido S, Malaponte G, Mazzarino MC, Fagone P, Nicoletti F, Bäsecke J, Mijatovic S, Maksimovic-Ivanic D, Milella M, Tafuri A, Chiarini F, Evangelisti C, Cocco L, Martelli AM: Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget. 2012, 3 (10): 1068-1111.
Article
PubMed
PubMed Central
Google Scholar
Borrello MG, Ardini E, Locati LD, Greco A, Licitra L, Pierotti MA: RET inhibition: implications in cancer therapy. Expert Opin Ther Targets. 2013, 17 (4): 403-419. 10.1517/14728222.2013.758715.
Article
CAS
PubMed
Google Scholar
Mologni L: Development of RET kinase inhibitors for targeted cancer therapy. Curr Med Chem. 2011, 18 (2): 162-175. 10.2174/092986711794088308.
Article
CAS
PubMed
Google Scholar
Phay JE, Shah MH: Targeting RET receptor tyrosine kinase activation in cancer. Clin Cancer Res. 2010, 16 (24): 5936-5941. 10.1158/1078-0432.CCR-09-0786.
Article
CAS
PubMed
Google Scholar
Bain J, McLauchlan H, Elliott M, Cohen P: The specificities of protein kinase inhibitors: an update. Biochem J. 2003, 371 (Pt 1): 199-204.
CAS
PubMed
PubMed Central
Google Scholar
Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, Klevernic I, Arthur JS, Alessi DR, Cohen P: The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007, 408 (3): 297-315. 10.1042/BJ20070797.
Article
CAS
PubMed
PubMed Central
Google Scholar
Caccia D, Micciche F, Cassinelli G, Mondellini P, Casalini P, Bongarzone I: Dasatinib reduces FAK phosphorylation increasing the effects of RPI-1 inhibition in a RET/PTC1-expressing cell line. Mol Cancer. 2010, 9: 278-10.1186/1476-4598-9-278.
Article
PubMed
PubMed Central
Google Scholar
Murakami H, Iwashita T, Asai N, Iwata Y, Narumiya S, Takahashi M: Rho-dependent and -independent tyrosine phosphorylation of focal adhesion kinase, paxillin and p130Cas mediated by Ret kinase. Oncogene. 1999, 18 (11): 1975-1982. 10.1038/sj.onc.1202514.
Article
CAS
PubMed
Google Scholar
Plaza-Menacho I, Morandi A, Mologni L, Boender P, Gambacorti-Passerini C, Magee AI, Hofstra RM, Knowles P, McDonald NQ, Isacke CM: Focal adhesion kinase (FAK) binds RET kinase via its FERM domain, priming a direct and reciprocal RET-FAK transactivation mechanism. J Biol Chem. 2011, 286 (19): 17292-17302. 10.1074/jbc.M110.168500.
Article
CAS
PubMed
PubMed Central
Google Scholar
Brandt W, Mologni L, Preu L, Lemcke T, Gambacorti-Passerini C, Kunick C: Inhibitors of the RET tyrosine kinase based on a 2-(alkylsulfanyl)-4-(3-thienyl)nicotinonitrile scaffold. Eur J Med Chem. 2010, 45 (7): 2919-2927. 10.1016/j.ejmech.2010.03.017.
Article
CAS
PubMed
Google Scholar
Carlomagno F, Vitagliano D, Guida T, Napolitano M, Vecchio G, Fusco A, Gazit A, Levitzki A, Santoro M: The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes. Cancer Res. 2002, 62 (4): 1077-1082.
CAS
PubMed
Google Scholar
Hanke JH, Gardner JP, Dow RL, Changelian PS, Brissette WH, Weringer EJ, Pollok BA, Connelly PA: Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation. J Biol Chem. 1996, 271 (2): 695-701.
CAS
PubMed
Google Scholar
Lanzi C, Cassinelli G, Cuccuru G, Zaffaroni N, Supino R, Vignati S, Zanchi C, Yamamoto M, Zunino F: Inactivation of Ret/Ptc1 oncoprotein and inhibition of papillary thyroid carcinoma cell proliferation by indolinone RPI-1. Cell Mol Life Sci. 2003, 60 (7): 1449-1459. 10.1007/s00018-003-2381-8.
Article
CAS
PubMed
Google Scholar
Cassinelli G, Lanzi C, Petrangolini G, Tortoreto M, Pratesi G, Cuccuru G, Laccabue D, Supino R, Belluco S, Favini E, Poletti A, Zunino F: Inhibition of c-Met and prevention of spontaneous metastatic spreading by the 2-indolinone RPI-1. Mol Cancer Ther. 2006, 5 (9): 2388-2397. 10.1158/1535-7163.MCT-06-0245.
Article
CAS
PubMed
Google Scholar
Lanzi C, Cassinelli G, Pensa T, Cassinis M, Gambetta RA, Borrello MG, Menta E, Pierotti MA, Zunino F: Inhibition of transforming activity of the ret/ptc1 oncoprotein by a 2-indolinone derivative. Int J Cancer. 2000, 85 (3): 384-390. 10.1002/(SICI)1097-0215(20000201)85:3<384::AID-IJC15>3.0.CO;2-Y.
Article
CAS
PubMed
Google Scholar
Meulenbeld HJ, Mathijssen RH, Verweij J, de Wit R, de Jonge MJ: Danusertib, an aurora kinase inhibitor. Expert Opin Investig Drugs. 2012, 21 (3): 383-393. 10.1517/13543784.2012.652303.
Article
CAS
PubMed
Google Scholar
Pardanani A, Hood J, Lasho T, Levine RL, Martin MB, Noronha G, Finke C, Mak CC, Mesa R, Zhu H, Soll R, Gilliland DG, Tefferi A: TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia. 2007, 21 (8): 1658-1668. 10.1038/sj.leu.2404750.
Article
CAS
PubMed
Google Scholar
Arora A, Scholar EM: Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther. 2005, 315 (3): 971-979. 10.1124/jpet.105.084145.
Article
CAS
PubMed
Google Scholar
Mendel DB, Schreck RE, West DC, Li G, Strawn LM, Tanciongco SS, Vasile S, Shawver LK, Cherrington JM: The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function. Clin Cancer Res. 2000, 6 (12): 4848-4858.
CAS
PubMed
Google Scholar
Kim A, Balis FM, Widemann BC: Sorafenib and sunitinib. Oncologist. 2009, 14 (8): 800-805. 10.1634/theoncologist.2009-0088.
Article
CAS
PubMed
Google Scholar
Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, Qian F, Chu F, Bentzien F, Cancilla B, Orf J, You A, Laird AD, Engst S, Lee L, Lesch J, Chou YC, Joly AH: Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011, 10 (12): 2298-2308. 10.1158/1535-7163.MCT-11-0264.
Article
CAS
PubMed
Google Scholar
Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, Schwartz B, Simantov R, Kelley S: Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 2006, 5 (10): 835-844. 10.1038/nrd2130.
Article
CAS
PubMed
Google Scholar
Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, Vecchio G, Ryan AJ, Fontanini G, Fusco A, Santoro M: ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res. 2002, 62 (24): 7284-7290.
CAS
PubMed
Google Scholar
Ciardiello F, Tortora G: A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res. 2001, 7 (10): 2958-2970.
CAS
PubMed
Google Scholar
Mologni L, Redaelli S, Morandi A, Plaza-Menacho I, Gambacorti-Passerini C: Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase. Mol Cell Endocrinol. 2013, 377 (1–2): 1-6.
Article
CAS
PubMed
Google Scholar
O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, Adrian LT, Zhou T, Huang WS, Xu Q, Metcalf CA, Tyner JW, Loriaux MM, Corbin AS, Wardwell S, Ning Y, Keats JA, Wang Y, Sundaramoorthi R, Thomas M, Zhou D, Snodgrass J, Commodore L, Sawyer TK, Dalgarno DC, Deininger MW, Druker BJ, Clackson T: AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009, 16 (5): 401-412. 10.1016/j.ccr.2009.09.028.
Article
PubMed
PubMed Central
Google Scholar
Akeno-Stuart N, Croyle M, Knauf JA, Malaguarnera R, Vitagliano D, Santoro M, Stephan C, Grosios K, Wartmann M, Cozens R, Caravatti G, Fabbro D, Lane HA, Fagin JA: The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells. Cancer Res. 2007, 67 (14): 6956-6964. 10.1158/0008-5472.CAN-06-4605.
Article
CAS
PubMed
Google Scholar
Morandi A, Martin LA, Gao Q, Pancholi S, Mackay A, Robertson D, Zvelebil M, Dowsett M, Plaza-Menacho I, Isacke CM: GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors. Cancer Res. 2013, 73 (12): 3783-3795. 10.1158/0008-5472.CAN-12-4265.
Article
CAS
PubMed
PubMed Central
Google Scholar
Lucet IS, Fantino E, Styles M, Bamert R, Patel O, Broughton SE, Walter M, Burns CJ, Treutlein H, Wilks AF, Rossjohn J: The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. Blood. 2006, 107 (1): 176-183. 10.1182/blood-2005-06-2413.
Article
CAS
PubMed
Google Scholar
Diner P, Alao JP, Soderlund J, Sunnerhagen P, Grotli M: Preparation of 3-Substituted-1-Isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amines as RET Kinase Inhibitors. J Med Chem. 2012, 55 (10): 4872-4876. 10.1021/jm3003944.
Article
CAS
PubMed
Google Scholar
Jiang J, Wei Y, Shen J, Liu D, Chen X, Zhou J, Zong H, Yun X, Kong X, Zhang S, Yang Y, Gu J: Functional interaction of E1AF and Sp1 in glioma invasion. Mol Cell Biol. 2007, 27 (24): 8770-8782. 10.1128/MCB.02302-06.
Article
CAS
PubMed
PubMed Central
Google Scholar
Pilli T, Prasad KV, Jayarama S, Pacini F, Prabhakar BS: Potential utility and limitations of thyroid cancer cell lines as models for studying thyroid cancer. Thyroid. 2009, 19 (12): 1333-1342. 10.1089/thy.2009.0195.
Article
CAS
PubMed
PubMed Central
Google Scholar
Saiselet M, Floor S, Tarabichi M, Dom G, Hebrant A, van Staveren WC, Maenhaut C: Thyroid cancer cell lines: an overview. Front Endocrinol. 2012, 3: 133-
Article
CAS
Google Scholar
Preto A, Gonçalves J, Rebocho AP, Figueiredo J, Meireles AM, Rocha AS, Vasconcelos HM, Seca H, Seruca R, Soares P, Sobrinho-Simões M: Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations. BMC Cancer. 2009, 9: 387-10.1186/1471-2407-9-387.
Article
PubMed
PubMed Central
Google Scholar
Slack-Davis JK, Martin KH, Tilghman RW, Iwanicki M, Ung EJ, Autry C, Luzzio MJ, Cooper B, Kath JC, Roberts WG, Parsons JT: Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem. 2007, 282 (20): 14845-14852. 10.1074/jbc.M606695200.
Article
CAS
PubMed
Google Scholar
Boulay A, Breuleux M, Stephan C, Fux C, Brisken C, Fiche M, Wartmann M, Stumm M, Lane HA, Hynes NE: The Ret receptor tyrosine kinase pathway functionally interacts with the ERalpha pathway in breast cancer. Cancer Res. 2008, 68 (10): 3743-3751. 10.1158/0008-5472.CAN-07-5100.
Article
CAS
PubMed
Google Scholar
Gattelli A, Nalvarte I, Boulay A, Roloff TC, Schreiber M, Carragher N, Macleod KK, Schlederer M, Lienhard S, Kenner L, Torres-Arzayus MI, Hynes NE: Ret inhibition decreases growth and metastatic potential of estrogen receptor positive breast cancer cells. EMBO Mol Med. 2013, 5 (9): 1335-1350. 10.1002/emmm.201302625.
Article
CAS
PubMed
PubMed Central
Google Scholar
St Bernard R, Zheng L, Liu W, Winer D, Asa SL, Ezzat S: Fibroblast growth factor receptors as molecular targets in thyroid carcinoma. Endocrinology. 2005, 146 (3): 1145-1153. 10.1210/en.2004-1134.
Article
CAS
PubMed
Google Scholar
Kim DW, Hwang JH, Suh JM, Kim H, Song JH, Hwang ES, Hwang IY, Park KC, Chung HK, Kim JM, Park J, Hemmings BA, Shong M: RET/PTC (rearranged in transformation/papillary thyroid carcinomas) tyrosine kinase phosphorylates and activates phosphoinositide-dependent kinase 1 (PDK1): an alternative phosphatidylinositol 3-kinase-independent pathway to activate PDK1. Mol Endocrinol. 2003, 17 (7): 1382-1394. 10.1210/me.2002-0402.
Article
CAS
PubMed
Google Scholar
Knauf JA, Kuroda H, Basu S, Fagin JA: RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase. Oncogene. 2003, 22 (28): 4406-4412. 10.1038/sj.onc.1206602.
Article
CAS
PubMed
Google Scholar
Murphy LC, Seekallu SV, Watson PH: Clinical significance of estrogen receptor phosphorylation. Endocr Relat Cancer. 2011, 18 (1): R1-R14. 10.1677/ERC-10-0070.
Article
CAS
PubMed
Google Scholar
Yamnik RL, Holz MK: mTOR/S6K1 and MAPK/RSK signaling pathways coordinately regulate estrogen receptor alpha serine 167 phosphorylation. FEBS Lett. 2010, 584 (1): 124-128. 10.1016/j.febslet.2009.11.041.
Article
CAS
PubMed
Google Scholar
Gonzalez L, Agullo-Ortuno MT, Garcia-Martinez JM, Calcabrini A, Gamallo C, Palacios J, Aranda A, Martin-Perez J: Role of c-Src in human MCF7 breast cancer cell tumorigenesis. J Biol Chem. 2006, 281 (30): 20851-20864. 10.1074/jbc.M601570200.
Article
CAS
PubMed
Google Scholar
Alao JP: The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol Cancer. 2007, 6: 24-
Article
PubMed
PubMed Central
Google Scholar
Alao JP, Lam EW, Ali S, Buluwela L, Bordogna W, Lockey P, Varshochi R, Stavropoulou AV, Coombes RC, Vigushin DM: Histone deacetylase inhibitor trichostatin A represses estrogen receptor alpha-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines. Clin Cancer Res. 2004, 10 (23): 8094-8104. 10.1158/1078-0432.CCR-04-1023.
Article
CAS
PubMed
Google Scholar
Fox BP, Kandpal RP: Invasiveness of breast carcinoma cells and transcript profile: Eph receptors and ephrin ligands as molecular markers of potential diagnostic and prognostic application. Biochem Biophys Res Commun. 2004, 318 (4): 882-892. 10.1016/j.bbrc.2004.04.102.
Article
CAS
PubMed
Google Scholar
Simiantonaki N, Jayasinghe C, Michel-Schmidt R, Peters K, Hermanns MI, Kirkpatrick CJ: Hypoxia-induced epithelial VEGF-C/VEGFR-3 upregulation in carcinoma cell lines. Int J Oncol. 2008, 32 (3): 585-592.
CAS
PubMed
Google Scholar